KIA
PETX

Kopp Investment Advisors’s Aratana Therapeutics, Inc. PETX Stock Holding History

Kopp Investment Advisors’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-35,200
Closed -$575K – 78
2013
Q3 		$575K Sell
35,200
-18,095
-34% -$190K 0.21% 80
2013
Q2 		$403K Buy
+53,295
New +$422K 0.16% 84

Other funds holding PETX

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Kopp Investment Advisors's PETX Position: Q4 2013 in Review

Kopp Investment Advisors sold out of Aratana Therapeutics, Inc. (PETX) in Q4 2013, closing a stake of 35,200 shares — an estimated $575K sold.

Kopp Investment Advisors first reported a position in PETX in Q2 2013 and held it in 2 quarters. The position peaked at $575K in Q3 2013. 46 funds tracked by Wall St. Rank hold PETX as of Q4 2013.

  • Kopp Investment Advisors reported no remaining Aratana Therapeutics, Inc. position as of Q4 2013 after selling out during the quarter.
  • Kopp Investment Advisors sold 35,200 Aratana Therapeutics, Inc. shares in Q4 2013, an estimated $575K.
  • Kopp Investment Advisors first reported a position in Aratana Therapeutics, Inc. in Q2 2013 and held it in 2 quarters.
  • Kopp Investment Advisors's Aratana Therapeutics, Inc. position peaked at $575K in Q3 2013.
  • 46 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q4 2013.

Based on Kopp Investment Advisors's 13F filing for Q4 2013, filed 21 Jan 2014.